Compare SNPS & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNPS | SNY |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.2B | 119.4B |
| IPO Year | 1992 | N/A |
| Metric | SNPS | SNY |
|---|---|---|
| Price | $432.01 | $50.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $556.33 | $61.50 |
| AVG Volume (30 Days) | 2.2M | ★ 2.2M |
| Earning Date | 12-10-2025 | 10-24-2025 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | 31.64 | ★ 105.93 |
| EPS | ★ 12.67 | 8.67 |
| Revenue | $6,435,304,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | $17.26 | $2.37 |
| Revenue Next Year | $37.38 | $6.51 |
| P/E Ratio | $56.47 | ★ $11.32 |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $365.74 | $44.62 |
| 52 Week High | $651.73 | $60.12 |
| Indicator | SNPS | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 51.27 |
| Support Level | $376.69 | $49.14 |
| Resistance Level | $405.91 | $50.61 |
| Average True Range (ATR) | 13.32 | 0.73 |
| MACD | 6.92 | -0.13 |
| Stochastic Oscillator | 80.21 | 40.00 |
Synopsys is a provider of electronic design automation software and intellectual property products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Synopsys' comprehensive portfolio is benefiting from a convergence of semiconductor companies moving up the stack of technologies toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.